Source / Disclosures
The authors do not report any relevant financial disclosures.
Older, overweight women who received cardiotoxic treatment for breast cancer experienced a 15% relative reduction in cardiovascular disease risk after following an 8-week restricted eating plan, according to research published in JACC: Cardiology.
In a one-arm feasibility study, researchers also found that older breast cancer survivors who followed a time-limited eating plan reduced calorie intake without losing lean mass, and also experienced a reduction in visceral adipose tissue, which can predict CV events. .
“Time-restricted eating is an easy way to describe and track an intervention that may reduce body fat and CV risk,” Amy Kirkham, Ph.D., An assistant professor at the University of Toronto and an associate scientist at the Toronto Rehabilitation Institute, told Healio. “Further study is required to confirm these effects in randomized controlled trials, but this study demonstrates that time-restricted eating is feasible and associated with a lower symptom burden for older adults or breast cancer survivors who are overweight or obese.”
Breast cancer survivors at risk of cardiovascular disease
Kirkham and colleagues analyzed data from 22 women aged at least 60 years who were breast cancer survivors and were overweight (BMI 25 kg/m2).2) and risk factors for cardiovascular mortality, who completed cardiotoxic therapy (anthracyclines within 1 to 6 years). The researchers asked participants to eat ad libitum between noon and 8 p.m. on weekdays and any time of day on weekends, but only consume water, black coffee, or black tea outside of those hours for 8 weeks. No other instructions regarding dietary or physical activity were given. The women received behavioral support that included a phone call from a registered dietitian prior to the intervention, check-in calls from study staff at 1, 3 and 6 weeks and automated text messages twice daily inquiring about eating times. Commitment was determined through text messages. Calorie intake was assessed by an average of 3 days of 24-h diet records that were recorded during the first and last 2 weeks of the intervention.
The median age of the woman was 67 years. The median time since anthracycline treatment was 3 years and 50% received left-sided radiation; 91% of the women took tamoxifen and/or an aromatase inhibitor during the study. At baseline, 68% of the women were classified as ‘cardiovascular unhealthy’, defined as meeting criteria for metabolic syndrome or for treatment with statins.
During the intervention, the lean mass did not change (mean, -0.1 kg; q = 76) and calorie intake changed an average of – 450 kcal, which is a relative decrease of 22% (s .001).
The mean Framingham risk of CVD in women decreased from 10.9% to 8.6%, a relative change of -15% (q = .037). However, modifiable components of Framingham such as total cholesterol, HDL and systolic BP were generally unchanged, indicating interindividual differences in each of these measurements.
At 8 weeks, 53% of the women no longer met the criteria for pharmacotherapy for risk of cardiovascular disease or metabolic syndrome and were reclassified as low risk for cardiovascular disease in Framingham (<10%).
Participants reported mild and transient symptoms during the time-restricted eating intervention of headache and irritability.
Possible risk mitigation strategy
The researchers noted that breast cancer survivors with a low risk of cardiovascular disease in Framingham had 38% fewer cardiac events than those at average risk, adding that long-term reclassification to a lower risk of Framingham CVD or reversal of CVD Metabolism can reduce healthcare costs and improve outcomes.
“If these findings can be replicated in a randomized controlled trial, time-restricted eating could be used as a simple, cost-effective, and safe treatment that can be prescribed in the clinic as an alternative to drug CV risk-reducing therapies,” Kirkland said. Helio. This study was a single-arm feasibility trial, which means that it did not have a control group. In order to confirm study results indicating a positive effect on visceral fat and CV, a randomized controlled trial will be the next step.”
for more information:
Amy Kirkham, Ph.D., She can be reached at email@example.com; Twitter: @amyakirkham.